Skip to Content
MilliporeSigma
All Photos(1)

Documents

D0125000

Daunorubicin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Daunomycin hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H29NO10 · HCl
CAS Number:
23541-50-6
Molecular Weight:
563.98
Beilstein/REAXYS Number:
4229221
MDL number:
MFCD04974507
UNSPSC Code:
41116107
PubChem Substance ID:
329798585
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

daunorubicin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O

InChI

1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1

InChI key

GUGHGUXZJWAIAS-QQYBVWGSSA-N

Gene Information

human ... TOP2A(7153)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Daunorubicin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Potent anticancer agent. Inhibits DNA and RNA synthesis as sequence specific ds-DNA intercalating agent.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2 - Muta. 2 - Repr. 1B

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 6

1 of 6

USP

USP

1225758

Doxorubicinone

Doxorubicin hydrochloride suitable for fluorescence, 98.0-102.0% (HPLC)

Sigma-Aldrich

44583

Doxorubicin hydrochloride

Doxorubicin hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1225703

Doxorubicin hydrochloride

Doxorubicin hydrochloride British Pharmacopoeia (BP) Reference Standard

BP990

Doxorubicin hydrochloride

Doxorubicin Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1789

Doxorubicin Hydrochloride

Fucoidan from Fucus vesiculosus ≥95%

Sigma-Aldrich

F8190

Fucoidan from Fucus vesiculosus

I-Shan Hsieh et al.
Molecular pharmacology, 83(5), 968-977 (2013-02-26)
Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an
S Park et al.
Leukemia, 27(7), 1479-1486 (2013-01-17)
The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional chemotherapy, in AML patients under 65 years of age
Onkar S Bains et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 375-387 (2013-09-03)
The role of metabolism in daunorubicin (DAUN)- and doxorubicin (DOX)-associated toxicity in cancer patients is dependent on whether the parent drugs or major metabolites, doxorubicinol (DOXol) and daunorubicinol (DAUNol), are the more toxic species. Therefore, we examined whether an association
Jay Chhablani et al.
Investigative ophthalmology & visual science, 54(2), 1268-1279 (2013-01-17)
To test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system. Porous silicon was heat oxidized and chemically functionalized so that the functional
Cedric Dos Santos et al.
Blood, 122(11), 1900-1913 (2013-07-31)
The SRC family kinases (SFKs) and the receptor tyrosine kinase c-Kit are activated in human acute myeloid leukemia (AML) cells. We show here that the SFKs LYN, HCK, or FGR are overexpressed and activated in AML progenitor cells. Treatment with
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service